Peter Wark

Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Australia | John Hunter Hospital, Newcastle, Australia | See Acknowledgements section.

Severe Asthma | Elexacaftor Tezacaftor Ivacaftor | People Cystic Fibrosis | F508del Mutation | Evidence Taskforce

KOL Resume for Peter Wark

Year
2022	Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Australia
2020	See Acknowledgements section.

Prominent publications by Peter Wark

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, doubl

[ PUBLICATION ]

KOL-Index: 4518

BACKGROUND: Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe and efficacious in people with cystic fibrosis aged 12 years or older with at least one F508del-CFTR allele. We aimed to assess the magnitude and durability of the clinical effects of this triple combination regimen in people with cystic fibrosis homozygous for the F508del-CFTR mutation.

METHODS: We ...

Known for Cystic Fibrosis | Elexacaftor Tezacaftor Ivacaftor | Week 24 | Homozygous F508del | Sweat Chloride

Clinical care of pregnant and postpartum women with COVID‐19: Living recommendations from the National COVID‐19 Clinical Evidence Taskforce

[ PUBLICATION ]

KOL-Index: 3373

To date, 18 living recommendations for the clinical care of pregnant and postpartum women with COVID-19 have been issued by the National COVID-19 Clinical Evidence Taskforce. This includes recommendations on mode of birth, delayed umbilical cord clamping, skin-to-skin contact, breastfeeding, rooming-in, antenatal corticosteroids, angiotensin-converting enzyme inhibitors, disease-modifying treatments (including dexamethasone, remdesivir and hydroxychloroquine), venous thromboembolism ...

Known for Evidence Taskforce | National Covid‐19 | Prone Positioning | Covid19 Clinical | Complications Infectious

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

[ PUBLICATION ]

KOL-Index: 2035

BACKGROUND: Clinicians are increasingly recognizing severe asthma patients in whom biologics and other add-on therapies lead to dramatic improvement. Currently, there is no agreed-upon super-responder (SR) definition.

OBJECTIVE: To survey severe asthma experts using a modified Delphi process, to develop an international consensus-based definition of a severe asthma SR.

METHODS: The Delphi panel was composed of 81 participants (94% specialist pulmonologists or allergists) from 24 ...

Known for Severe Asthma | Quality Life | 12 Months | Patients Biologics

Key People For Severe Asthma

Top KOLs in the world

Sally E Wenzel

severe asthma lung function epithelial cells

Kian Fan Chung

severe asthma chronic cough alveolar macrophages

Eugene R Bleecker

severe asthma lung function prostate cancer

Pascal CHANEZ

severe asthma bronchial thermoplasty epithelial cells

M del R Castro

severe asthma lung function bronchial thermoplasty

Peter Jan Sterk

severe asthma electronic nose exhaled breath

Select a search phrase severe asthma , severe asthma patients , severe asthma exacerbations , severe asthmatics , severe asthma children

Peter Wark:Expert Impact

Concepts for whichPeter Warkhas direct influence:Severe asthma, Elexacaftor tezacaftor ivacaftor, Patients severe asthma, People cystic fibrosis, F508del mutation, Tezacaftor ivacaftor, Elexacaftor tezacaftor, Eosinophilic asthma.

Peter Wark:KOL impact

Concepts related to the work of other authors for whichfor which Peter Wark has influence:Severe asthma, Clinical remission, Prone position, Infant feeding, Routing problem, Crispr dark matter, Advanced lung disease.

Tools

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile https://www.keyopinionleaders.com/Severe-Asthma/Peter-Wark-Immune-Health-Program-Hunter-Medical-Re-dfda6ef34f7a4af60540988ee557cbfc-gr.html

Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Australia | John Hunter Hospital, Newcastle, Australia | See Acknowledgements section.